NTT: World’s First Successful 1.4-Tbit/s Wireless Transmission in the Sub-THz Band
17.5.2023 11:09:00 EEST | Business Wire | Press release
Aiming to implement terabit-class wireless transmission to support wireless demand in the 2030s, NTT Corporation (NTT) has successfully achieved the world’s first “orbital angular momentum (OAM) multiplexing high-capacity wireless transmission—at 1.44 Tbit/s—using an ultra-wide bandwidth of 32 GHz. As an innovative wireless-communication technology that uses the sub-terahertz (sub-THz) band, this achievement will enable wireless access to vast amounts of information at data-transfer rate exceeding 1 Tbit/s. This achievement was realized using the sub-THz band within the range from 135 GHz to 170 GHz, and is an innovative wireless communication technology that enables wireless access to a huge amount of information exceeding 1 Tbit/s. As a key element of the “Innovative Optical and Wireless Network” (IOWN), which we aim to implement with our global partners, it is an extension of the high-capacity communication network and information-processing infrastructure centered on light to wireless networks including 6G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420006084/en/
Figure 1: Image of OAM-multiplexing transmission technology and trends in high-capacity wireless transmission (Graphic: Business Wire)
Aiming to support the high-capacity network and information processing infrastructure of the IOWN and 6G and prepare for the increasing future demand for wireless communications, NTT is engaged in research and development with the goal of achieving terabit-class wireless transmission. To enhance the capacity of wireless communications, NTT is increasing the spatial multiplexing order by applying on a new principle using radio waves with “orbital angular momentum” (Figure 1) to increase wireless-transmission capacity and using the sub-terahertz (sub-THz) band to increase transmission bandwidth.
The approach taken by NTT is to use an analog circuit called a “Butler matrix” to increase the spatial multiplexing order by multiplexing multiple OAM waves. This approach reduces the enormous amount of digital signal processing required to eliminate interference between multiplexed data streams in high-capacity communications exceeding one terabit.
In this research, NTT has promoted research and development of sub-THz-band waveguide technology and succeeded in developing an antenna-integrated Butler matrix that operates with a wide bandwidth and low loss. The antenna-integrated Butler matrix is designed to simultaneously generate and separate eight different OAM waves over a very wide bandwidth, i.e., 135 to 170 GHz, which can be used to multiplex and transmit eight data signals. Moreover, by performing OAM multiplexing transmission with two different polarizations, it is possible to multiplex and transmit twice as many data signals simultaneously without them interfering. We conducted transmission tests using the antenna-integrated Butler matrix, and we achieved the world’s first successful large-capacity wireless transmission totaling 1.44 Tbit/s in the sub-THz bands of 135.5 to 151.5 GHz and 152.5 to 168.5 GHz (Figure 2). This transmission capacity is equivalent to the speed of simultaneous transmission of approximately 35,000 ultra-high-definition 4K videos (at about 40 Mbit/s) that can be available on current video websites. This speed enables the simultaneous transmission of 140 or more uncompressed 4K videos (at about 10 Gbit/s) for applications that require ultra-low latency.
This technology is expected to enable (i) broadband and high-speed wireless transmission comparable to optical transmission systems and (ii) seamless connection between wireless and optical transmission systems without the need for a complex digital signal-processing system for spatial multiplexing, since the analog circuit (i.e., the Butler matrix) handles the multiplexing of OAM waves. The next step in this development is to conduct demonstrations over longer distances (exceeding 100 m) while envisioning various applications of this technology in the real world, including wireless backhaul/fronthaul between base stations and relay transmission (Figure 3). We expect the eventual development of this technology to support the creation and spread of various future services, such as VR/AR (virtual reality/augmented reality), high-definition video transmission, connected cars, and telemedicine, as innovative wireless-communication technology in the IOWN and 6G era.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230420006084/en/
Contact information
[Media Contact]
NTT Corporation,
Science and Core Technology Laboratory Group,
nttrd-pr@ml.ntt.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
